CDK4/6-话题@MedSci

#CDK4/6#

47篇内容 | 2308人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1490683, encodeId=4ccd149068305, content=<a href='/topic/show?id=2765440372' target=_blank style='color:#2F92EE;'>#CDK4/6#</a>, objectTitle=CLIN CANCER RES：肢端黑色素瘤CDK4通路基因改变表明CDK4/6抑制可以作为靶向疗法, objectType=article, longId=121178, objectId=6c591211e82d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6c591211e82d, replyNumber=0, likeNumber=110, createdTime=2017-11-25, rootId=0, userName=zhangj7111, userId=c7068807080, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6c591211e82d, moduleTitle=CLIN CANCER RES：肢端黑色素瘤CDK4通路基因改变表明CDK4/6抑制可以作为靶向疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6c591211e82d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490682, encodeId=38a8149068228, content=<a href='/topic/show?id=2765440372' target=_blank style='color:#2F92EE;'>#CDK4/6#</a>, objectTitle=Nature：CDK4/6抑制剂--ER+乳腺癌治疗新选择!, objectType=article, longId=118337, objectId=fa9711833ec4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa9711833ec4, replyNumber=0, likeNumber=79, createdTime=2017-11-02, rootId=0, userName=zhangj7111, userId=c7068807080, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa9711833ec4, moduleTitle=Nature：CDK4/6抑制剂--ER+乳腺癌治疗新选择!, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fa9711833ec4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490681, encodeId=9050149068143, content=<a href='/topic/show?id=2765440372' target=_blank style='color:#2F92EE;'>#CDK4/6#</a>, objectTitle=[SIBCS2017]在故事开始的地方，Richard S. Finn教授谈CDK4/6抑制剂成功的漫漫长路, objectType=article, longId=117554, objectId=372411e55468, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=372411e55468, replyNumber=0, likeNumber=0, createdTime=2017-10-27, rootId=0, userName=zhangj7111, userId=c7068807080, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=372411e55468, moduleTitle=[SIBCS2017]在故事开始的地方，Richard S. Finn教授谈CDK4/6抑制剂成功的漫漫长路, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=372411e55468)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490680, encodeId=cea5149068062, content=<a href='/topic/show?id=2765440372' target=_blank style='color:#2F92EE;'>#CDK4/6#</a>, objectTitle=Nature：惊人发现！“重磅抗癌药”CDK4/6抑制剂竟然也是免疫疗法, objectType=article, longId=110335, objectId=e6bf1103359b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e6bf1103359b, replyNumber=0, likeNumber=95, createdTime=2017-08-22, rootId=0, userName=zhangj7111, userId=c7068807080, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e6bf1103359b, moduleTitle=Nature：惊人发现！“重磅抗癌药”CDK4/6抑制剂竟然也是免疫疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e6bf1103359b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490679, encodeId=859d14906e9d6, content=<a href='/topic/show?id=2765440372' target=_blank style='color:#2F92EE;'>#CDK4/6#</a>, objectTitle=Oncologist:乳腺癌CDK4/6抑制剂治疗的潜在副作用都有啥？, objectType=article, longId=106365, objectId=2cb21063650c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2cb21063650c, replyNumber=0, likeNumber=78, createdTime=2017-07-24, rootId=0, userName=zhangj7111, userId=c7068807080, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2cb21063650c, moduleTitle=Oncologist:乳腺癌CDK4/6抑制剂治疗的潜在副作用都有啥？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2cb21063650c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490678, encodeId=135e14906e8f4, content=<a href='/topic/show?id=2765440372' target=_blank style='color:#2F92EE;'>#CDK4/6#</a>, objectTitle=Nature：这一指标可预测CDK4/6抑制剂抗癌效果, objectType=article, longId=101718, objectId=b103101e18e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b103101e18e7, replyNumber=0, likeNumber=84, createdTime=2017-06-15, rootId=0, userName=zhangj7111, userId=c7068807080, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b103101e18e7, moduleTitle=Nature：这一指标可预测CDK4/6抑制剂抗癌效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b103101e18e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490677, encodeId=f2cb14906e7be, content=<a href='/topic/show?id=2765440372' target=_blank style='color:#2F92EE;'>#CDK4/6#</a>, objectTitle=以CDK4/6为靶点的三种乳腺癌新药均取得不俗进展能延长晚期乳癌患者生命, objectType=article, longId=33202, objectId=9d173320207, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d173320207, replyNumber=0, likeNumber=94, createdTime=2014-04-12, rootId=0, userName=zhangj7111, userId=c7068807080, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d173320207, moduleTitle=以CDK4/6为靶点的三种乳腺癌新药均取得不俗进展能延长晚期乳癌患者生命, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d173320207)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490676, encodeId=77c114906e6be, content=<a href='/topic/show?id=2765440372' target=_blank style='color:#2F92EE;'>#CDK4/6#</a>, objectTitle=辉瑞CDK4/6抑制剂palbociclib II期达主要终点, objectType=article, longId=33003, objectId=65bc330037a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=65bc330037a, replyNumber=0, likeNumber=86, createdTime=2014-04-10, rootId=0, userName=zhangj7111, userId=c7068807080, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=65bc330037a, moduleTitle=辉瑞CDK4/6抑制剂palbociclib II期达主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=65bc330037a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

CDK4/6

2020-05-29

zhangj7111 (审核中...)

前往app查看评论内容

#CDK4/6#

CLIN CANCER RES：肢端黑色素瘤CDK4通路基因改变表明CDK4/6抑制可以作为靶向疗法

2017-11-25

zhangj7111 (审核中...)

前往app查看评论内容

#CDK4/6#

Nature：CDK4/6抑制剂--ER+乳腺癌治疗新选择!

2017-11-02

zhangj7111 (审核中...)

前往app查看评论内容

#CDK4/6#

[SIBCS2017]在故事开始的地方，Richard S. Finn教授谈CDK4/6抑制剂成功的漫漫长路

2017-10-27

zhangj7111 (审核中...)

前往app查看评论内容

#CDK4/6#

Nature：惊人发现！“重磅抗癌药”CDK4/6抑制剂竟然也是免疫疗法

2017-08-22

zhangj7111 (审核中...)

前往app查看评论内容

#CDK4/6#

Oncologist:乳腺癌CDK4/6抑制剂治疗的潜在副作用都有啥？

2017-07-24

zhangj7111 (审核中...)

前往app查看评论内容

#CDK4/6#

Nature：这一指标可预测CDK4/6抑制剂抗癌效果

2017-06-15

zhangj7111 (审核中...)

前往app查看评论内容

#CDK4/6#

以CDK4/6为靶点的三种乳腺癌新药均取得不俗进展能延长晚期乳癌患者生命

2014-04-12

zhangj7111 (审核中...)

前往app查看评论内容

#CDK4/6#

辉瑞CDK4/6抑制剂palbociclib II期达主要终点

2014-04-10

科室
- - 订阅+
  - 更多科室
工具
服务